Wilms’ tumour and chemotherapeutic access
African Journal of Paediatric Surgery · 26.05.2026 · 12 (3) · 208
DOI: 10.67481/ajps.v12i3.679 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Journal of Paediatric Surgery, online erschienen am 26.05.2026. Verfasst von Sora Yasri.
Abstract (Originalsprache)
We enjoy reading the recent report on ‘Wilms’ tumour and chemotherapeutic access’.[1] Anyanwa et al. reported that ‘an institutionalised approach can help to improve access to anti-cancer drugs, reduce the rate of loss to follow-up and thus improve outcome’.[1] In fact, the problem of anticancer drug access can be seen in many developing countries. In a previous report by Uba and Chirdan, ‘poor availability of cytotoxic drugs’ is an important factor contributing to the poor outcome of disease in Nigeria.[2] It is suggested that pre-operative combined chemotherapy is required for the better operative curative outcome of paediatric cases of Wilms’ tumours.[3] To manage the high cost of chemotherapy, some new studies show that metronomic chemotherapy can be the hope for the management of the problem.
Zitieren
APA
Yasri, S. (2026). Wilms’ tumour and chemotherapeutic access. African Journal of Paediatric Surgery, 12(3), 208. https://doi.org/10.67481/ajps.v12i3.679
Vancouver
Yasri S. Wilms’ tumour and chemotherapeutic access. African Journal of Paediatric Surgery. 2026;12(3):208. doi:10.67481/ajps.v12i3.679
BibTeX
@article{Yasri2026,
author = {Yasri, Sora},
title = {Wilms’ tumour and chemotherapeutic access},
journal = {African Journal of Paediatric Surgery},
year = {2026},
volume = {12},
number = {3},
pages = {208},
doi = {10.67481/ajps.v12i3.679}
}
EUVIMED